Skip to main content
. 2022 Nov 17;14(22):5643. doi: 10.3390/cancers14225643

Figure 2.

Figure 2

Patient outcomes of BC survival on the METABRIC and the Nottingham BC cohorts. (A) Cumulative survival of BC patients stratified by CDCA5 mRNA expression in the KM-Plotter cohort. (B) Cumulative survival of BC patients stratified by CDCA5 mRNA expression in breast tumors in METABRIC. (C) Cumulative survival of BC patients stratified by CDCA5 mRNA expression in LVI-positive BC in METABRIC. (D) Cumulative survival of BC stratified by CDCA5 protein expression. (E) Cumulative survival of BC patients stratified by CDCA5 protein expression in the Nottingham LVI-positive cohort.